









Markets
/
Stocks
/
nasdaq-rzlt
/

Rezolute Inc

RZLT

3.120USD

+0.200+6.85%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

284.03MMarket Cap

LossP/E TTM



Rezolute Inc

3.120

+0.200+6.85%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rezolute Inc

Currency: USD Updated: 2026-02-06

Key Insights

Rezolute Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 99 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.25.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rezolute Inc's Score

Industry at a Glance

Industry Ranking

99 / 392

Overall Ranking

228 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Rezolute Inc Highlights

StrengthsRisks

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -3.34, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 102.48M shares, increasing 10.16% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 323.70K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.14.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

6.250

Target Price

+114.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Rezolute Inc is 5.45, ranking 363 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.45

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Rezolute Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Rezolute Inc is 6.36, ranking 289 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.34, which is -79.91% below the recent high of -0.67 and -250.64% above the recent low of -11.71.

Score

Industry at a Glance

Previous score

6.36

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 99/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Rezolute Inc is 7.80, ranking 267 out of 392 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 20.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

7.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

6.250

Target Price

+114.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Rezolute Inc

RZLT

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Rezolute Inc is 8.82, ranking 53 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.76 and the support level at 2.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.41

Change

1.41

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.197

Neutral

RSI(14)

46.378

Neutral

STOCH(KDJ)(9,3,3)

29.835

Neutral

ATR(14)

0.274

High Vlolatility

CCI(14)

-38.517

Neutral

Williams %R

55.208

Sell

TRIX(12,20)

0.008

Sell

StochRSI(14)

85.378

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

3.068

Buy

MA10

3.219

Sell

MA20

3.038

Buy

MA50

4.166

Sell

MA100

6.669

Sell

MA200

5.944

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Rezolute Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 110.52%, representing a quarter-over-quarter increase of 21.13%. The largest institutional shareholder is The Vanguard, holding a total of 4.79M shares, representing 5.16% of shares outstanding, with 85.92% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Federated Hermes Global Investment Management Corp.

14.03M

Fidelity Management & Research Company LLC

12.35M

-1.04%

RA Capital Management, LP

9.18M

Handok Inc

8.42M

+17.11%

Opaleye Management Inc.

4.91M

+443.80%

Invus Public Equities Advisors, LLC

4.87M

The Vanguard Group, Inc.

Star Investors

4.41M

+9.63%

BlackRock Institutional Trust Company, N.A.

4.54M

+21.70%

Blackstone Alternative Asset Management, L.P.

3.02M

-15.07%

Mangrove Partners

2.88M

+25.45%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Rezolute Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.53. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.